![](https://www.biopharmadive.com/imgproxy/N-DWxqUxHVCJI8udyVmrhOliGPJlEKo_qBMaiWeKtE0/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0FtYXpvbl9QaGFybWFjeS5qcGc=.webp)
Amazon expands drug subscription program to Medicare members
Dive Brief: Amazon has expanded its generic drug savings program to Prime members on Medicare, throwing open the program’s doors
Read MoreJuly 4, 2024
Dive Brief: Amazon has expanded its generic drug savings program to Prime members on Medicare, throwing open the program’s doors
Read MoreDive Brief: Twice-yearly shots of a Gilead Sciences HIV drug were so effective at preventing infections in a large late-stage
Read MoreAn experimental weight loss shot developed by Denmark-based Zealand Pharma helped people with obesity lose as much as 9% of
Read MoreToday, a brief rundown of news from Jazz Pharma, Vanda Pharmaceuticals, ITM, Ashibio and Novartis that you might have missed
Read MorePeter Marks is again at the center of a controversial Food and Drug Administration decision on a gene therapy for
Read MoreThe Food and Drug Administration has substantially loosened limits on the first gene therapy for Duchenne muscular dystrophy in a
Read MoreDive Brief: PTC Therapeutics said Thursday it can resume a Phase 2 trial of its Huntington’s disease drug in the
Read MoreRoche has partnered with Ascidian Therapeutics to develop so-called “RNA exon editing” drugs, the latest foray by the Swiss pharmaceutical
Read MoreToday, a brief rundown of news from Belharra Therapeutics, AstraZeneca, Regenxbio and Tasyha Gene Therapies. Sanofi will work with biotechnology
Read MoreDive Brief: Intra-Cellular Therapies plans to seek clearance to sell its medicine Caplyta for patients with depression after a second-late
Read More